Dimopoulos M A, O'Brien S, Kantarjian H, Estey E E, Keating M J, Alexanian R
Department of Hematology, University of Texas, M. D. Anderson Cancer Center, Houston 77030.
Leuk Lymphoma. 1993;11 Suppl 2:105-8. doi: 10.3109/10428199309064269.
Sixty-eight patients with Waldenstrom's macroglobulinemia were treated either with fludarabine (28 patients) or 2-chlorodeoxyadenosine (40 patients) and responding patients were followed without further treatment. Both programs were well tolerated and myelosuppression was moderate but reversible. Overall, 35 patients responded including 93% of previously untreated patients, 83% of those relapsing off therapy, 48% of patients with primary refractory disease and 15% of those treated during refractory relapse. With a median follow up of 18 months, only two of 15 previously untreated patients have relapsed whereas the median remission duration and survival of previously treated patients were 38 and 43 months respectively. Fludarabine and 2-chlorodeoxyadenosine are both highly active agents against Waldenstrom's macroglobulinemia, especially when administered early in the disease course.
68例华氏巨球蛋白血症患者接受了氟达拉滨（28例患者）或2-氯脱氧腺苷（40例患者）治疗，对有反应的患者未进行进一步治疗而进行随访。两个治疗方案耐受性均良好，骨髓抑制为中度但可逆转。总体而言，35例患者有反应，包括93%的既往未治疗患者、83%的治疗后复发患者、48%的原发性难治性疾病患者以及15%的难治性复发期间接受治疗的患者。中位随访18个月时，15例既往未治疗患者中仅2例复发，而既往接受治疗患者的中位缓解持续时间和生存期分别为38个月和43个月。氟达拉滨和2-氯脱氧腺苷都是治疗华氏巨球蛋白血症的高效药物，尤其是在疾病病程早期使用时。
